SC
TLX

Steven Cohen’s Telix Pharmaceuticals TLX Stock Holding History

Steven Cohen’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,409
Closed -$138K – 4664
2025
Q4 		$138K Buy
+18,409
New +$177K ﹤0.01% 3699

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return

Steven Cohen's TLX Position: Q1 2026 in Review

Steven Cohen sold out of Telix Pharmaceuticals (TLX) in Q1 2026, closing a stake of 18,409 shares — an estimated $138K sold.

Steven Cohen first reported a position in TLX in Q4 2025 and held it in 1 quarter. The position peaked at $138K in Q4 2025. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • Steven Cohen reported no remaining Telix Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Steven Cohen sold 18,409 Telix Pharmaceuticals shares in Q1 2026, an estimated $138K.
  • Steven Cohen first reported a position in Telix Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Steven Cohen's Telix Pharmaceuticals position peaked at $138K in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.